A phase II trial of anlotinib and fulvestrant in patients with metastatic breast cancer previously treated with an aromatase inhibitor

被引：0
|
作者：
Wang, X. [1 ]
Huang, J. [1 ]
Wenyan, C. [2 ]
Sun, Z. [3 ]
Wei, S. [2 ]
Wang, L. [3 ]
机构：
[1] Zhejiang Canc Hosp, Dept Med Oncol, Hangzhou, Peoples R China
[2] Nanchang Peoples Hosp, Dept Breast Med Oncol, Nanchang, Jiangxi, Peoples R China
[3] Jiangxi Canc Hosp, Dept Breast Surg, Nanchang, Jiangxi, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.628
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
452P
引用
收藏
页码：S371 / S371
页数：1
相关论文
共 50 条
  • [1] Fulvestrant in metastatic breast cancer previously treated with aromatase inhibitors
    Ribeiro, J.
    Luis, I.
    Fortunato, M.
    Correia, L.
    Quintela, A.
    Cortes, P.
    Costa, L.
    EJC SUPPLEMENTS, 2008, 6 (07): : 180 - 180
  • [2] Randomized Phase II Trial of Fulvestrant with or without Dasatinib in Postmenopausal Patients with Hormone Receptor-Positive Metastatic Breast Cancer Previously Treated with an Aromatase Inhibitor.
    Wright, G. L.
    Blum, J.
    Krekow, L. K.
    McIntyre, K. J.
    Wilks, S. T.
    Rabe, A. C.
    Vukelja, S. J.
    Andersen, J. C.
    Wang, Y.
    Asmar, L.
    O'Shaughnessy, J.
    CANCER RESEARCH, 2011, 71
  • [3] N0539 phase II trial of fulvestrant and bevacizumab in patients with metastatic breast cancer previously treated with an aromatase inhibitor: a North Central Cancer Treatment Group (now Alliance) trial
    Tan, W. W.
    Dueck, A. C.
    Flynn, P.
    Steen, P.
    Anderson, D.
    Rowland, K.
    Northfelt, D.
    Perez, E. A.
    ANNALS OF ONCOLOGY, 2013, 24 (10) : 2548 - 2554
  • [4] A phase II trial of anlotinib and fulvestrant in patients with HR-positive and HER2-negative, secondary aromatase inhibitor-resistant, metastatic breast cancer
    Wang, Xiaojia
    Huang, Jian
    Chen, Wenyan
    Sun, Zhengkui
    Liu, Jian
    Cui, Jiuwei
    Wei, Songzhi
    Lv, Zheng
    Wu, Fan
    Yu, Tenghua
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [5] A Phase II Trial of Fulvestrant and RAD001 (Everolimus) in Patients with Metastatic Estrogen Receptor Positive Breast Cancer after Aromatase Inhibitor Failure; a Study in Progress
    Badin, F.
    Romond, E.
    Chambers, M.
    Shelton, B.
    Birk, S.
    Kadamyan, V.
    Weiss, H.
    Massarweh, S.
    CANCER RESEARCH, 2010, 70
  • [6] Pegylated liposomal doxorubicin in previously treated patients with metastatic breast cancer - a large multicenter phase II trial
    Al-Batran, SE
    Bischoff, J
    von Minckwitz, G
    Atmaca, A
    Kleeberg, U
    Meuthen, I
    Morack, G
    Lerbs, W
    Hccker, D
    Jager, E
    BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S280 - S280
  • [7] Oral metronomic administration of cyclophosphamide and vinorelbine in previously treated patients with metastatic breast cancer: Phase II trial
    Pluma Jimenez, M. A.
    Perez, M.
    Bautista Aragon, Y. L.
    Villalobos, R.
    Rivera, S.
    Ortiz, K.
    Avila, G. G.
    Silva, A. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [8] N0539 Phase II Trial of Fulvstrant and Bevacizumab in Patients with Metastatic Breast Cancer Previouslly Treated with an Aromatase Inhibitor: A North Central Cancer Treatment Group Trial
    Tan, W. W.
    Dueck, A. C.
    Flynn, P.
    Steen, P.
    Anderson, D.
    Rowland, K.
    Nothfeldt, D.
    Lingle, W.
    Copland, J.
    Perez, E. A.
    CANCER RESEARCH, 2009, 69 (24) : 738S - 738S
  • [9] A phase II study of combined fulvestrant and everolimus in patients with metastatic estrogen receptor (ER)-positive breast cancer after aromatase inhibitor (AI) failure
    Massarweh, Suleiman
    Romond, Edward
    Black, Esther P.
    Van Meter, Emily
    Shelton, Brent
    Kadamyan-Melkumian, Vera
    Stevens, Mark
    Elledge, Richard
    BREAST CANCER RESEARCH AND TREATMENT, 2014, 143 (02) : 325 - 332
  • [10] A phase II study of combined fulvestrant and everolimus in patients with metastatic estrogen receptor (ER)-positive breast cancer after aromatase inhibitor (AI) failure
    Suleiman Massarweh
    Edward Romond
    Esther P. Black
    Emily Van Meter
    Brent Shelton
    Vera Kadamyan-Melkumian
    Mark Stevens
    Richard Elledge
    Breast Cancer Research and Treatment, 2014, 143 : 325 - 332
12345